MCD 386

Drug Profile

MCD 386

Alternative Names: CDD-0102; CDD-0102-J; MCD-386; MCD-386 Forte; MCD-386 Forte/Transderm; MCD-386 Transderm; MCD-386CR

Latest Information Update: 10 May 2011

Price : $50

At a glance

  • Originator University of Toledo
  • Developer Mithridion
  • Class Antidementias; Oxadiazoles; Pyrimidines; Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors; Muscarinic M1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progressive supranuclear palsy
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Alzheimer's disease
  • Preclinical Progressive supranuclear palsy; Schizophrenia

Most Recent Events

  • 09 May 2011 MCD 386 receives Orphan Drug status for Progressive supranuclear palsy in USA
  • 09 May 2011 Preclinical trials in Progressive supranuclear palsy in USA (PO)
  • 12 Jan 2011 MCD 386 is available for licensing as of 12 Jan 2011. http://www.mithridion.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top